Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical Practice
Author:
- 23 April 2010
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 11 (5) , 657-660
Abstract
The past decade of pharmacogenomics was driven by the sequencing of the human genome to create ever denser maps of genetic variations for studying the diversity across individuals. Today, genotyping technology is available at a fraction of the cost of what it was 10 years ago and many pharmacogenomic variations have been studied in detail. Still, we are only starting to gain an understanding of how pharmacogenomic-guided drug therapy affects clinical outcomes: real-world studies that demonstrate the clinical effectiveness and address the economic implications of pharmacogenomics are needed to help decide when and how to implement pharmacogenomics in clinical practice, how to regulate pharmacogenomic testing and how the healthcare system will integrate this new science into an environment of rapidly increasing cost.Keywords
Funding Information
- Medco Health Solutions, Inc.
This publication has 10 references indexed in Scilit:
- Economic Opportunities and Challenges for PharmacogenomicsAnnual Review of Pharmacology and Toxicology, 2010
- Health Spending Growth At A Historic Low In 2008Health Affairs, 2010
- Chutes and Ladders on the Critical Path:Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug DevelopmentClinical Pharmacology & Therapeutics, 2009
- Payer Perspectives on Pharmacogenomics Testing and Drug DevelopmentPharmacogenomics, 2008
- 4th US FDA–Drug Information Association Pharmacogenomics Workshop, Held 10–12 December, 2007Pharmacogenomics, 2008
- Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug UsePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshopThe Pharmacogenomics Journal, 2006
- Translation of pharmacogenomics and pharmacogenetics: a regulatory perspectiveNature Reviews Drug Discovery, 2004
- Pharmacogenomic-guided drug development: regulatory perspectiveThe Pharmacogenomics Journal, 2002
- Clinical application of pharmacogeneticsTrends in Molecular Medicine, 2001